M605106

M605106 is an investigational topical small molecule being developed by Maruho Co., Ltd. for the treatment of axillary osmidrosis, a condition characterized by unpleasant underarm odor resulting from the bacterial decomposition of apocrine sweat. The drug is formulated for short-contact topical application, a regimen where the product is applied to the axillary region and then washed off after a brief period, intended to balance therapeutic efficacy with skin tolerability. M605106 is currently in Phase II clinical development in Japan, where it is being evaluated for its ability to reduce axillary odor scores and its overall safety profile in adult patients. While the specific molecular target has not been publicly disclosed, the treatment likely functions by modulating the cutaneous microbiome or inhibiting the production of odorous volatile organic compounds.